Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-16T16:01:30.019Z Has data issue: false hasContentIssue false

Serum S100B protein after electroconvulsive therapy in patients with depression

Published online by Cambridge University Press:  07 March 2022

Krzysztof Gbyl*
Affiliation:
Center for Neuropsychiatric Depression Research (CNDR), Mental Health Center Glostrup, Glostrup, DenmarkInstitute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Niklas Rye Jørgensen
Affiliation:
Department of Clinical Biochemistry, Rigshospitalet-Glostrup, Glostrup, DenmarkInstitute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Poul Videbech
Affiliation:
Center for Neuropsychiatric Depression Research (CNDR), Mental Health Center Glostrup, Glostrup, DenmarkInstitute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
*
Author for correspondence: Krzysztof Gbyl, Email: krzysztof.gbyl@regionh.dk
Rights & Permissions [Opens in a new window]

Abstract

Objective:

S100B is a glial cell protein with bimodal function. In low concentrations, it exerts neurotrophic effects, but higher levels reflect neuronal distress. Recent research suggests that this molecule may be a biomarker of response to electroconvulsive therapy (ECT). We examined the effect of ECT on serum S100B and its utility as 1) a biomarker of a depressive state and 2) a predictor of ECT response. We also wanted to ensure that ECT does not cause a marked serum S100B elevation, indicating neural distress.

Methods:

We measured serum S100B in 22 in-patients treated with ECT due to depression. Depression severity was assessed using 17-item Hamilton Rating Scale for Depression (HAMD-17). The data were collected before an ECT series, within 1 week after the series (post-ECT), and at a 6-month follow-up. Changes in serum S100B and clinical outcomes were tested using a linear mixed model. A relationship between serum S100B and the clinical outcomes was examined using Spearman’s and partial correlation.

Results:

Serum S100B did not change significantly immediately after an ECT series or 6 months later. The post-ECT serum S100B change was not associated with the clinical effect (rho = 0.14, n = 22, p = 0.54). The baseline serum S100B did not predict the clinical effect when controlling for age (r = 0.02, n = 22, df = 19, p = 0.92).

Conclusion:

The study neither supports serum S100B as a state marker of depression nor a predictor of ECT response. No evidence for ECT-related neural distress was found.

Information

Type
Original Article
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of Scandinavian College of Neuropsychopharmacology
Figure 0

Table 1.Clinical characteristics of the sample and the course of ECT

Figure 1

Fig. 1.Serum S100B changes following an ECT series in individual participants (a) and presented as the sample means (b). Error bars on Fig. 1b depict 1 standard deviation of the sample mean. ng/L, nanograms per litre; n.s., non-significant; pre-ECT, within 2 days before an ECT series; post-ECT, within 1 week after an ECT series; six-month follow-up, 6 months after an ECT series.

Figure 2

Table 2.The change in serum S100B

Supplementary material: PDF

Gbyl et al. supplementary material

Table S1

Download Gbyl et al. supplementary material(PDF)
PDF 29.4 KB